Stock CYTO ALTAMIRA THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

News Altamira Therapeutics Nasdaq

Equities

CYTO

BMG0360L2099

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.69 USD +5.62% Intraday chart for Altamira Therapeutics +19.52% -51.44%
Apr. 24 Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal CI
Apr. 10 Transcript : Altamira Therapeutics Ltd., 2023 Earnings Call, Apr 10, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
AQ
Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
CI
Altamira Therapeutics : Notice of the Annual General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on May 16, 2024 - Form 6-K
PU
Transcript : Altamira Therapeutics Ltd., 2023 Earnings Call, Apr 10, 2024
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
AQ
Altamira Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
AQ
Sector Update: Health Care Stocks Decline Late Afternoon
MT
Top Midday Gainers
MT
Sector Update: Health Care Stocks Softer in Afternoon Trading
MT
Altamira, Univercells Partner to Test mRNA Vaccine Delivery; Shares Surge
MT
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
AQ
Altamira Therapeutics Ltd. Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
CI
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
AQ
Altamira Therapeutics? Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
CI
Altamira Files Second Provisional Patent Application in Cancer Treatment; Shares Rise
MT
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
AQ
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
CI
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
AQ
Altamira Therapeutics Back in Compliance with Nasdaq Minimum Bid Price Rules
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYTO Stock
  4. CYTO Stock
  5. News Altamira Therapeutics